<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Boundless Bio, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock</link>
<description>Latest news and press releases for Boundless Bio, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:49:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/boundless-bio-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354edd78dffbe2df0e68b0.webp</url>
<title>Boundless Bio, Inc. Common Stock</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock</link>
</image>
<item>
<title>Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-program-at-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-program-at-2026-aacr-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 20:49:00 GMT</pubDate>
<description>Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancersSAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical data supporting its l</description>
</item>
<item>
<title>Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-upcoming-presentation-of-oral-kinesin-degrader-program-at-the-american-association-for-cancer-research-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-upcoming-presentation-of-oral-kinesin-degrader-program-at-the-american-association-for-cancer-research-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)</description>
</item>
<item>
<title>Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected</description>
</item>
<item>
<title>Boundless Bio to Participate in the Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-to-participate-in-the-leerink-global-healthcare-conference-7</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-to-participate-in-the-leerink-global-healthcare-conference-7</guid>
<pubDate>Wed, 04 Mar 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference. The fireside chat session is scheduled for Wednesday, March 11, in Miami, Flor</description>
</item>
<item>
<title>Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-guggenheim-emerging-120000138</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-guggenheim-emerging-120000138</guid>
<pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The fireside chat session is scheduled for Thursday, February 12, i</description>
</item>
<item>
<title>Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-advances-novel-kinesin-120000331</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-advances-novel-kinesin-120000331</guid>
<pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
<description>BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today a</description>
</item>
<item>
<title>Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-piper-sandler-120000330</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-piper-sandler-120000330</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in</description>
</item>
<item>
<title>Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-third-quarter-120000219</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-third-quarter-120000219</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DN</description>
</item>
<item>
<title>Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-upcoming-presentation-200500897</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-upcoming-presentation-200500897</guid>
<pubDate>Mon, 13 Oct 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Details of the presentations are as follows: Tit</description>
</item>
<item>
<title>Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-second-quarter-110000078</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-second-quarter-110000078</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver</description>
</item>
<item>
<title>Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-goldman-sachs-205800118</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-goldman-sachs-205800118</guid>
<pubDate>Thu, 05 Jun 2025 20:58:00 GMT</pubDate>
<description>SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in</description>
</item>
<item>
<title>Boundless Bio Announces Portfolio Prioritization and Runway Extension</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-portfolio-prioritization-200100423</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-portfolio-prioritization-200100423</guid>
<pubDate>Fri, 23 May 2025 20:01:00 GMT</pubDate>
<description>Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)</description>
</item>
<item>
<title>Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-first-quarter-110000131</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-first-quarter-110000131</guid>
<pubDate>Fri, 09 May 2025 11:00:00 GMT</pubDate>
<description>Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) bio</description>
</item>
<item>
<title>Boundless Bio to Participate in the Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-needham-virtual-110000640</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-needham-virtual-110000640</guid>
<pubDate>Thu, 03 Apr 2025 11:00:00 GMT</pubDate>
<description>SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham’s Virtual Healthcare Conference. A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and arch</description>
</item>
<item>
<title>Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-fourth-quarter-110000185</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-fourth-quarter-110000185</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolo</description>
</item>
<item>
<title>Boundless Bio to Participate in the Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-leerink-global-120000893</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-participate-leerink-global-120000893</guid>
<pubDate>Wed, 26 Feb 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET.</description>
</item>
<item>
<title>Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-appoints-robert-doebele-md-phd-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-appoints-robert-doebele-md-phd-as-chief-medical-officer</guid>
<pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
<description>- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer</description>
</item>
<item>
<title>Boundless Bio Announces Pipeline and Leadership Updates</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-pipeline-and-leadership-updates</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-pipeline-and-leadership-updates</guid>
<pubDate>Thu, 12 Dec 2024 05:00:00 GMT</pubDate>
<description>Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate</description>
</item>
<item>
<title>Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-third-quarter-2024-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-reports-third-quarter-2024-financial-results-and-business-highlights</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash</description>
</item>
<item>
<title>Boundless Bio Announces Departure of Chief Financial Officer</title>
<link>https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-departure-of-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/boundless-bio-inc-common-stock/news/boundless-bio-announces-departure-of-chief-financial-officer</guid>
<pubDate>Mon, 14 Oct 2024 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)</description>
</item>
</channel>
</rss>